comparative agent
Recently Published Documents


TOTAL DOCUMENTS

4
(FIVE YEARS 1)

H-INDEX

3
(FIVE YEARS 0)

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Indushree Banerjee ◽  
Martijn Warnier ◽  
Frances M. T. Brazier ◽  
Dirk Helbing

AbstractParticipatory resilience of disaster-struck communities requires reliable communication for self-organized rescue, as conventional communication infrastructure is damaged. Disasters often lead to blackouts preventing citizens from charging their phones, leading to disparity in battery charges and a digital divide in communication opportunities. We propose a value-based emergency communication system based on participatory fairness, ensuring equal communication opportunities for all, regardless of inequality in battery charge. The proposed infrastructure-less emergency communication network automatically and dynamically (i) assigns high-battery phones as hubs, (ii) adapts the topology to changing battery charges, and (iii) self-organizes to remain robust and reliable when links fail or phones leave the network. The novelty of the proposed mobile protocol compared to mesh communication networks is demonstrated by comparative agent-based simulations. An evaluation using the Gini coefficient demonstrates that our network design results in fairer participation of all devices and a longer network lifetime, benefiting the community and its participants.


1997 ◽  
Vol 41 (9) ◽  
pp. 1916-1921 ◽  
Author(s):  
G S Perdikaris ◽  
A Pefanis ◽  
H Giamarellou ◽  
A Nikolopoulos ◽  
E P Margaris ◽  
...  

Teicoplanin is a glycopeptide antibiotic that is administered both intramuscularly and intravenously. It has a prolonged half-life and a less toxic profile in comparison to those of vancomycin. The efficacy of a single dose of teicoplanin (18 mg/kg of body weight given intramuscularly) for the prevention of endocarditis due to Streptococcus oralis, Enterococcus faecium, and methicillin-resistant Staphylococcus aureus (MRSA) was evaluated after applying the rabbit model. Vancomycin at a single dose of 30 mg/kg given intravenously was used as the comparative agent for the prevention of endocarditis due to MRSA and E. faecium, while ampicillin at a single dose of 40 mg/kg given intravenously was used as the comparative agent for the prevention of endocarditis due to S. oralis. Rabbits in the teicoplanin group were infected at 1 h postdosing with approximately 10(7) CFU of each strain. Rabbits in the other groups were infected at 0.5 h postdosing with approximately 10(7) CFU of S. oralis (ampicillin group) or E. faecium and MRSA (vancomycin group). All rabbits were sacrificed 5 days later. Teicoplanin and vancomycin protected the animals challenged with E. faecium by 87.5 and 50%, respectively, and protected the animals challenged with MRSA by 100 and 92%, respectively. Teicoplanin and ampicillin protected the animals challenged with S. oralis by 100 and 77%, respectively. Prevention of endocarditis by teicoplanin was likely to be due to a prolonged inhibition of bacterial growth by the sustained supra-MICs. It is concluded that teicoplanin is very effective in preventing experimental streptococcal, enterococcal, and staphylococcal endocarditis and may be an attractive alternative antibiotic in patients allergic to beta-lactams, especially in the outpatient setting.


Sign in / Sign up

Export Citation Format

Share Document